Starting April 16, peptide search traffic spiked roughly 400% across the internet. Dozens of new sellers appeared overnight. A lot of questionable marketing copy suddenly started claiming "FDA approved."
Nothing the FDA did on April 15 approved anything. Here is the honest buyer's guide — the one we wish every new peptide customer read before their first order.
Five rules before you buy anything
Rule 1: Reclassified is not approved
The FDA removed twelve peptides from its Category 2 "Do Not Compound" list effective April 22, 2026. That is step one of a multi-step process. Until the Pharmacy Compounding Advisory Committee (PCAC) votes — July 23–24 for the first seven peptides, a separate meeting before February 2027 for the remaining five — and the FDA publishes final rules, none of these peptides can be legally prescribed through a conventional 503A compounding pharmacy.
If a website says "FDA approved BPC-157" right now, close the tab. They are lying or uninformed. Neither is a reason to give them your credit card. For the full regulatory picture, see our main reclassification briefing.
Rule 2: Ask for the Certificate of Analysis
Every reputable peptide source — Apotheca included — should provide a per-lot Certificate of Analysis (COA) generated by an independent lab. The COA should show:
- Identity confirmation (mass spectrometry)
- Purity (HPLC, minimum 98%)
- Net peptide content (the differentiator — raw peptide weight vs. weight with counterions)
- Residual solvents
- Endotoxin level (critical for injectables)
- Date of analysis matching your lot number
If the seller cannot produce this document within thirty seconds of being asked, you do not have a peptide — you have a gamble.
Rule 3: Know what you are actually buying by weight
A vial labeled "5 mg BPC-157" might contain:
- 5 mg of actual peptide (best case)
- 5 mg of peptide + counterions, trimming actual peptide content to roughly 4.2 mg (common)
- 5 mg total weight, with some portion being buffer salts (shady)
- Far less than 5 mg (counterfeit)
This is where net peptide content on the COA matters. Apotheca publishes net peptide weight on every SKU.
Rule 4: Evidence tier beats brand marketing
Not every peptide has equal evidence. Apotheca's internal tiering:
- Tier A — Multiple Phase III human RCTs (semaglutide, tirzepatide, tesamorelin)
- Tier B — Strong animal data plus limited positive human data (BPC-157, TB-500, MOTS-c)
- Tier C — Strong mechanism, preclinical only or early human signal (KPV, Epitalon, GHK-Cu injectable)
- Tier D — Mechanism plausible, data thin or inconsistent (many classical bioregulators)
- Tier E — Red flags (retracted foundational papers, documented adverse events)
Never pay Tier A prices for Tier D evidence.
Rule 5: Cycle, don't chase
Most peptides were never studied for continuous long-term use in humans. Practitioner consensus for injury-repair peptides:
- 4–12 weeks on
- 2–4 weeks off
- Reassess objectively (imaging, symptom diary, functional test) before continuing
Chronic uninterrupted use is common in community forums and unsupported by clinical evidence.
The Apotheca Peptide Trust Score — how we actually score peptides
We built the Peptide Trust Score (PTS) because there was no defensible framework for ranking peptides by what matters. Every SKU on apotheca.market runs through it.
PTS v2.0 has six dimensions, total 100 points:
| Dimension | Max | What it measures |
|---|---|---|
| D1 — Evidence Quality | 25 | RCT count, meta-analyses, study rigor |
| D2 — Regulatory Status | 20 | FDA, EMA, compounding pathway, recency |
| D3 — Safety Profile | 15 | Adverse events, contraindications, drug interactions |
| D4 — Practitioner Signal | 15 | Clinical adoption, prescribing patterns, reported outcomes |
| D5 — Community Consensus | 15 | Reddit, forums, Substack — real patient reports |
| D6 — Source Quality | 10 | COA rigor, sourcing chain, lot testing |
The tiers
- Elite (≥85) — FDA-approved or near-approved, extensive human data, clean safety
- Recommended (≥70) — Strong evidence, clear use case, established track record
- Verified (≥55) — Reasonable evidence, practitioner use, known safety profile
- Unscored (<55) — Insufficient evidence to recommend without case-by-case context
The post-reclassification tier shifts
Here is what changed at Apotheca as of April 20, 2026:
New or retained Elite (score ≥85):
- Semaglutide 5 mg — 100
- Tirzepatide 10 mg — 100
- Cagrilintide + Semaglutide — 92 (up from 86)
- Oxytocin — 91
- PT-141 — 89
- Tesamorelin — 86
Recommended (70–84):
- Thymosin Alpha-1 Immune — 75
- Thymosin Alpha-1 Healing — 75
- Cerebrolysin — 79 (up from 70)
Verified (55–69) — where most of the reclassified peptides landed:
- TB-500 — 69 (up from 63)
- BPC-157 Injectable — 65 (up from 59)
- BPC-157 Oral — 65 (up from 59)
- The Wolverine Stack — 67 (up from 61)
- GHK-Cu Injectable — 62 (up from 58)
- The KLOW Blend — 59.6 (up from 55.6)
- Semax — 65 (up from 56)
Delisted pending review:
- Any SKU containing DiHexa. Its foundational 2012 paper on cognitive-enhancement effects was retracted in 2025 for data-integrity concerns. Until independent replication clears the literature, Apotheca has taken standalone DiHexa, Matter Lucid, and the Cognitive Performance Stack offline. We will reinstate them only if the evidentiary record is restored.
A quick peptide sourcing checklist
When buying peptides from anyone — including us — check for:
- Physical address of the compounding or manufacturing facility
- Lot-specific Certificate of Analysis available within one click
- Net peptide content on the label, not just gross weight
- Published tier or score with a methodology you can read
- Clear list of ingredients, excipients, and solvents
- Return policy that applies to unopened vials
- Licensed clinician in the sourcing chain where compounding is involved
- No "FDA approved" language for peptides that are not FDA approved
- Transparent disclosure of research-use vs. pending-legal vs. prescription status
Apotheca hits all nine. If any peptide seller misses three or more, walk away.
Where this is headed
Between now and the July 23 PCAC meeting, expect:
- A wave of new peptide sellers — some legitimate, many not
- Aggressive marketing claims you should ignore
- Continued investment in clinical trials by established players
- Mainstream press coverage that will alternately over-hype and dismiss the entire category
The patients who come out ahead will be the ones who read carefully, source rigorously, and work with clinicians who know this space.
Final word
Peptides are powerful biologics. The post-April 15 environment has made them more accessible than at any point in the last three years — but accessibility is not the same as approval. Evidence is not the same as hype. A Certificate of Analysis matters more than any testimonial.
If you are going to participate in this wave, participate like an adult. Ask questions. Read evidence. Work with practitioners. Pick suppliers who publish their work.
Further reading
- The FDA Just Reclassified 12 Peptides. Here's What Actually Changed.
- BPC-157: The Pentadecapeptide That Went From Croatia to Congress
- FDA 503A Categories Update for April 2026 (PDF)
- Frier Levitt legal analysis of the April 15 notice
This guide is educational and not medical advice. Peptides should be used under the care of a qualified clinician who knows your medical history.